PAVmed Net Income Per E B T from 2010 to 2024

PAVMZ Stock  USD 0.01  0.01  40.94%   
PAVmed Series Net Income Per E B T yearly trend continues to be fairly stable with very little volatility. Net Income Per E B T is likely to outpace its year average in 2024. During the period from 2010 to 2024, PAVmed Series Net Income Per E B T regression line of annual values had r-squared of  0.20 and arithmetic mean of  0.97. View All Fundamentals
 
Net Income Per E B T  
First Reported
2010-12-31
Previous Quarter
0.80964637
Current Value
1.02
Quarterly Volatility
0.05277182
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check PAVmed Series financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PAVmed Series' main balance sheet or income statement drivers, such as Interest Expense of 559.5 K, Selling General Administrative of 32.5 M or Other Operating Expenses of 74.8 M, as well as many indicators such as Price To Sales Ratio of 11.54, Dividend Yield of 3.0E-4 or Days Sales Outstanding of 14.05. PAVmed financial statements analysis is a perfect complement when working with PAVmed Series Valuation or Volatility modules.
  
Check out the analysis of PAVmed Series Correlation against competitors.

Latest PAVmed Series' Net Income Per E B T Growth Pattern

Below is the plot of the Net Income Per E B T of PAVmed Series Z over the last few years. It is PAVmed Series' Net Income Per E B T historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PAVmed Series' overall financial position and show how it may be relating to other accounts over time.
Net Income Per E B T10 Years Trend
Slightly volatile
   Net Income Per E B T   
       Timeline  

PAVmed Net Income Per E B T Regression Statistics

Arithmetic Mean0.97
Geometric Mean0.96
Coefficient Of Variation5.46
Mean Deviation0.04
Median0.99
Standard Deviation0.05
Sample Variance0
Range0.2104
R-Value(0.45)
Mean Square Error0
R-Squared0.20
Significance0.09
Slope(0.01)
Total Sum of Squares0.04

PAVmed Net Income Per E B T History

2024 1.02
2023 0.81
2022 0.98
2021 0.9
2020 0.96
2019 0.92

About PAVmed Series Financial Statements

PAVmed Series investors use historical fundamental indicators, such as PAVmed Series' Net Income Per E B T, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in PAVmed Series. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Income Per E B T 0.81  1.02 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for PAVmed Stock Analysis

When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.